{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T12:34:49Z","timestamp":1777466089121,"version":"3.51.4"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["JP20K08926"],"award-info":[{"award-number":["JP20K08926"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s12282-026-01854-3","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T14:03:17Z","timestamp":1775052197000},"page":"722-735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integration of gene expression profiling and mutation analysis via RNA sequencing: transitioning the 95-gene classifier to a next-generation platform in early-stage HR+\/HER2- breast cancer"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6605-6907","authenticated-orcid":false,"given":"Chikage","family":"Kato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5963-652X","authenticated-orcid":false,"given":"Yoshiaki","family":"Sota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6896-3088","authenticated-orcid":false,"given":"Sae","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0496-5945","authenticated-orcid":false,"given":"Akira","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daitho","family":"Motonari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuria","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4083-4432","authenticated-orcid":false,"given":"Midori","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1412-0604","authenticated-orcid":false,"given":"Koichi","family":"Sakaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0837-2357","authenticated-orcid":false,"given":"Kenzo","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6090-0137","authenticated-orcid":false,"given":"Yasuto","family":"Naoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"6797","key":"1854_CR1","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, S\u00f8rlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352.","journal-title":"Nature"},{"issue":"27","key":"1854_CR2","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1056\/NEJMoa041588","volume":"351","author":"S Paik","year":"2004","unstructured":"Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817\u201326.","journal-title":"N Engl J Med"},{"issue":"23","key":"1854_CR3","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1200\/JCO.2005.04.7985","volume":"24","author":"S Paik","year":"2006","unstructured":"Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24(23):3726\u201334.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1854_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379(2):111\u201321.","journal-title":"N Engl J Med"},{"issue":"25","key":"1854_CR5","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Meric-Bernstam F, Gralow JR, Albain KS, Hayes DF, et al. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385(25):2336\u201347.","journal-title":"N Engl J Med"},{"issue":"3","key":"1854_CR6","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10549-010-1145-z","volume":"128","author":"Y Naoi","year":"2011","unstructured":"Naoi Y, Kishi K, Tanei T, Tsunashima R, Nakayama T, Maruyama N, et al. Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. Breast Cancer Res Treat. 2011;128(3):633\u201341.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1854_CR7","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1111\/cas.14838","volume":"112","author":"Y Naoi","year":"2021","unstructured":"Naoi Y, Tsunashima R, Shimazu K, Noguchi S. The multigene classifiers 95GC\/42GC\/155GC for precision medicine in ER-positive HER2-negative early breast cancer. Cancer Sci. 2021;112(4):1369\u201375.","journal-title":"Cancer Sci"},{"issue":"1","key":"1854_CR8","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1186\/s12885-021-08778-5","volume":"21","author":"F Tsukamoto","year":"2021","unstructured":"Tsukamoto F, Arihiro K, Takahashi M, Ito K, Ohsumi S, Takashima S, et al. Multicenter retrospective study on the use of Curebest\u2122 95GC Breast for estrogen receptor-positive and node-negative early breast cancer. BMC Cancer. 2021;21(1):1077.","journal-title":"BMC Cancer"},{"issue":"2","key":"1854_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10549-021-06276-7","volume":"189","author":"T Fujii","year":"2021","unstructured":"Fujii T, Masuda H, Cheng YC, Yang F, Sahin AA, Naoi Y, et al. A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Res Treat. 2021;189(2):455\u201361.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1854_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3892\/ol.2023.13794","volume":"25","author":"Y Naoi","year":"2023","unstructured":"Naoi Y, Tsunashima R, Shimazu K, Oikawa M, Imanishi S, Koyama H, et al. Validation of the prognosis of patients with ER-positive, HER2-negative, and node-negative invasive breast cancer classified as low risk by Curebest\u2122 95GC Breast in a multi-institutional registry study. Oncol Lett. 2023;25(5):209.","journal-title":"Oncol Lett"},{"issue":"2","key":"1854_CR11","doi-asserted-by":"publisher","first-page":"707","DOI":"10.21873\/anticanres.16209","volume":"43","author":"H Yamashita","year":"2023","unstructured":"Yamashita H, Hatanaka KC, Yamagishi K, Saito Y, Hamasaki K, Taniguchi M, et al. Evaluation of a 95-gene classifier of formalin-fixed paraffin-embedded tissues in ER-positive, HER2-negative, and node-negative breast cancer. Anticancer Res. 2023;43(2):707\u201311.","journal-title":"Anticancer Res"},{"issue":"6","key":"1854_CR12","first-page":"2680","volume":"42","author":"Y Naoi","year":"2019","unstructured":"Naoi Y, Saito Y, Kishi K, Shimoda M, Kagara N, Miyake T, et al. Development of recurrence risk score using a 95-gene classifier and its application to formalin-fixed paraffin-embedded tissues in ER-positive, HER2-negative, and node-negative breast cancer. Oncol Rep. 2019;42(6):2680\u20135.","journal-title":"Oncol Rep"},{"issue":"1","key":"1854_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrg2484","volume":"10","author":"Z Wang","year":"2009","unstructured":"Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009;10(1):57\u201363.","journal-title":"Nat Rev Genet"},{"issue":"11","key":"1854_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/nbt.2696","volume":"31","author":"GM Frampton","year":"2013","unstructured":"Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31(11):1023\u201331.","journal-title":"Nat Biotechnol"},{"issue":"20","key":"1854_CR15","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-mutated, hormone receptor\u2013positive advanced breast cancer. N Engl J Med. 2019;380(20):1929\u201340.","journal-title":"N Engl J Med"},{"issue":"22","key":"1854_CR16","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, et al. Capivasertib in hormone receptor\u2013positive advanced breast cancer. N Engl J Med. 2023;388(22):2058\u201370.","journal-title":"N Engl J Med"},{"issue":"2","key":"1854_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrg.2017.96","volume":"19","author":"M Cieslik","year":"2018","unstructured":"Cieslik M, Chinnaiyan AM. Cancer transcriptome profiling at the juncture of clinical translation. Nat Rev Genet. 2018;19(2):93\u2013108.","journal-title":"Nat Rev Genet"},{"issue":"12","key":"1854_CR18","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439\u201345.","journal-title":"Nat Genet"},{"issue":"1","key":"1854_CR19","doi-asserted-by":"publisher","first-page":"5258","DOI":"10.1038\/s41467-022-32828-6","volume":"13","author":"M Palafox","year":"2022","unstructured":"Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, et al. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER+ breast cancer. Nat Commun. 2022;13(1):5258.","journal-title":"Nat Commun"},{"issue":"5","key":"1854_CR20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/2159-8290.CD-13-0929","volume":"4","author":"BC Grabiner","year":"2014","unstructured":"Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, et al. A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. Cancer Discov. 2014;4(5):554\u201363.","journal-title":"Cancer Discov"},{"issue":"8","key":"1854_CR21","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ncb3582","volume":"19","author":"BG Bitler","year":"2017","unstructured":"Bitler BG, Wu S, Park PH, Hai Y, Aird KM, et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat Cell Biol. 2017;19(8):962\u201373.","journal-title":"Nat Cell Biol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01854-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01854-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:27:37Z","timestamp":1777382857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01854-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1854"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01854-3","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yasuto Naoi has received research funding from Sysmex, ONO, Daiichi-Sankyo and AstraZeneca, and honoraria from AstraZeneca, Pfizer, Eli Lilly, Daiichi-Sankyo and Chugai outside the submitted work; he holds joint patents with Sysmex including Curebest\u2122 95GC Breast (JP.5725274.B2).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study has been approved by the Ethics Review Board of Osaka University as an intervention study (14223-2) and three observational studies (14106-9, 14190-4, 18313-4).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}